Key Takeaways
- • Genesys Capital, a Toronto-based venture capital firm focused exclusively on life sciences, appointed Dr. Maxime Ranger as a Venture Partner, with plans for him to become a General Partner of Genesys Ventures IV LP later in 2022.
- • Dr. Ranger has worked with Genesys for 15 years, co-creating and leading three biopharma companies, and currently serves as CEO of Genesys portfolio company Giiant Pharma.
- • He will anchor Genesys' co-creation and start-up activity in Montreal, as the firm expands its footprint in Quebec, where up to 40% of its deal flow originates.
- • Genesys expects to make its first investments out of Genesys Ventures IV later in 2022.
Summary
Genesys Capital, a Toronto and Montreal-based venture capital firm that describes itself as one of the largest Canadian-based venture capital firms exclusively focused on life sciences, has appointed Dr. Maxime Ranger as a Venture Partner, according to a Business Wire announcement. Later this year, Dr. Ranger will transition into the role of General Partner of Genesys Ventures IV LP, the firm's fund vehicle.
Dr. Ranger has had a long-standing relationship with Genesys, having co-created and provided leadership to three biopharma companies alongside the firm over the past 15 years. He most recently co-founded Giiant Pharma, a Genesys portfolio company, and currently serves as its CEO. Jamie Stiff, Managing Director at Genesys Capital, said the firm had worked with Dr. Ranger across a number of projects and that he was "without a doubt a natural fit as a General Partner."
The appointment strengthens the firm's Quebec presence. Genesys first expanded into the Quebec market in 2008, and the firm says up to 40% of its deal flow now originates in the province. Dr. Ranger will complement Genesys' company-building expertise with his operating experience and his immersion in the Quebec life sciences ecosystem, anchoring the firm's co-creation and start-up activity in Montreal. The firm said the move is intended to extend its reach beyond its existing Toronto offices.
Dr. Ranger said he intends to help build start-up companies around disruptive technologies and shape the Quebec life science ecosystem. Genesys expects to make its first investments out of Genesys Ventures IV later in 2022.
Genesys' announced portfolio includes Aptinyx (NASDAQ: APTX), Fusion Pharmaceuticals (NASDAQ: FUSN), Invitae (NYSE: NVTA), and Profound Medical (NASDAQ: PROF), among other companies.
Dr. Ranger has had a long-standing relationship with Genesys, having co-created and provided leadership to three biopharma companies alongside the firm over the past 15 years. He most recently co-founded Giiant Pharma, a Genesys portfolio company, and currently serves as its CEO. Jamie Stiff, Managing Director at Genesys Capital, said the firm had worked with Dr. Ranger across a number of projects and that he was "without a doubt a natural fit as a General Partner."
The appointment strengthens the firm's Quebec presence. Genesys first expanded into the Quebec market in 2008, and the firm says up to 40% of its deal flow now originates in the province. Dr. Ranger will complement Genesys' company-building expertise with his operating experience and his immersion in the Quebec life sciences ecosystem, anchoring the firm's co-creation and start-up activity in Montreal. The firm said the move is intended to extend its reach beyond its existing Toronto offices.
Dr. Ranger said he intends to help build start-up companies around disruptive technologies and shape the Quebec life science ecosystem. Genesys expects to make its first investments out of Genesys Ventures IV later in 2022.
Genesys' announced portfolio includes Aptinyx (NASDAQ: APTX), Fusion Pharmaceuticals (NASDAQ: FUSN), Invitae (NYSE: NVTA), and Profound Medical (NASDAQ: PROF), among other companies.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.